ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2157

Resveratrol Counters Pro-Atherogenic Effects of Systemic Lupus Erythematosus and Rheumatoid Arthritis Plasma On Cholesterol Efflux in Human Macrophages

Allison B. Reiss1, Iryna Voloshyna1, Ofek Hai1, Michael J. Littlefield1, Elise Belilos2, Kristina B. Belostocki2, Lois A. Bonetti3, Gary C. Rosenblum2 and Steven E. Carsons4, 1Medicine, Winthrop University Hospital, Mineola, NY, 2Rheumatology, Winthrop University Hospital, Mineola, NY, 3Rheum & Immun, Winthrop University Hospital, Mineola, NY, 4Div of Rheumatology, Winthrop University Hospital, Mineola, NY

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Cardiovascular disease, Cholesterol, macrophages, polymerase chain reaction (PCR) and resveratrol

  • Tweet
  • Email
  • Print
Session Information

Session Title: Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy

Session Type: Abstract Submissions (ACR)

Background/Purpose: Our group has demonstrated that resveratrol, a plant polyphenol, possesses atheroprotective properties, enhancing expression of reverse cholesterol transport (RCT) proteins. We have reported that Systemic Lupus Erythematosus (SLE) and rheumatoid arthritis (RA) patients manifest a pattern of disturbance in expression of RCT genes that is atheroma-promoting. The cholesterol efflux proteins 27-hydroxylase, ATP binding cassette transporter (ABC) A1 and ABCG1 are suppressed by plasma from persons with these autoimmune rheumatic diseases. These proteins are crucial for efficient cholesterol efflux from macrophages, a process that prevents foam cell formation (FCF) and protects against atherosclerosis. This study examines whether resveratrol can protect macrophages from pro-atherogenic effects of SLE and RA plasma on cholesterol metabolism.

Methods: ABCA1, ABCG1 and 27-hydroxylase expression were evaluated in THP-1 human macrophages, a pertinent model of atherosclerosis. Cells were incubated for 18h in 10% pooled SLE, RA or normal human plasma (NHP) ± resveratrol (25µM). mRNA was isolated and reverse transcribed. The resulting cDNA was subjected to quantitative PCR with specific primers for each gene. Cell extracts were prepared for immunoblotting after 24h. FCF was quantified as % oil red O stained cells. Studies were done in triplicate.

Results: 10% SLE plasma suppressed ABCA1 and ABCG1 expression by 58.3 ± 15.5% (n=3, P<0.001) and 48.3 ± 18.7% (n=3, P<0.01) below NHP, respectively (NHP set as 100%). 10% RA plasma induced similar levels of ABC transporter downregulation.  27-hydroxylase message level fell by 36.2 ±12.8% and 49.1 ± 14.7% (n=3, P<0.01) below NHP, respectively for SLE and RA plasma. When THP-1 macrophages were incubated with SLE or RA plasma + resveratrol, the resveratrol significantly negated downregulation of efflux proteins, restoring levels to that observed with NHP (Fig 1). FCF by THP-1 macrophages was significantly reduced by addition of resveratrol compared to SLE or RA plasma alone (by 22.2±5.1% and 35±7.5%, respectively [n=3, P<0.01]).

Conclusion: Resveratrol is able to counteract pro-atherogenic factors in SLE and RA plasma. Resveratrol acts as an anti-atherogenic agent by preventing lipid overload via effects on cholesterol transport. Since resveratrol has a strong safety profile and is well-tolerated, low cost, and can be used in combination with multiple other therapies without contraindication, these findings provide the rationale for a novel therapeutic approach to decrease the cardiovascular consequences of RA and SLE. Administration of resveratrol in these groups of patients might restore a critical defense mechanism against atherosclerosis and cardiovascular disease progression. Further in vivo studies are indicated for this promising treatment option.

 

Fig 1. *-P<0.05; ** P<0.01; *** P<0.001 vs. NHP; # P<0.05, ## P<0.01 vs. corresponding plasma without resveratrol.


Disclosure:

A. B. Reiss,
None;

I. Voloshyna,
None;

O. Hai,
None;

M. J. Littlefield,
None;

E. Belilos,
None;

K. B. Belostocki,
None;

L. A. Bonetti,
None;

G. C. Rosenblum,
None;

S. E. Carsons,
None.

  • Tweet
  • Email
  • Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/resveratrol-counters-pro-atherogenic-effects-of-systemic-lupus-erythematosus-and-rheumatoid-arthritis-plasma-on-cholesterol-efflux-in-human-macrophages/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies